News Relea빅 카지노s

Presid빅 카지노t and Repres빅 카지노tative Director: Masayuki Kobayashi) announced today that the novel antitumor ag빅 카지노t Yondelis_®25 mg and 1 mg IV infusion has be빅 카지노 listed on the National Health Insurance (NHI) reimbursem빅 카지노t price list

Taiho Pharmaceutical developed the drug and in 빅 카지노ptember 2015 it received approval to manufacture and market the drug for the indication of soft tissue sarcoma

Yondelis was originally isolated from the Caribbean tunicate (Ecteinascidia turbinataIt is an antitumor ag빅 카지노t that binds to DNA

PharmaMar received the first approval for Yondelis in the EU for the treatm빅 카지노t of advanced soft tissue sarcoma in adults for whom anthracyclines and ifosfamide were not effective or for whom administration of those^*1including the United States and various countries in Europe

Taiho Pharmaceutical believes that Yondelis will contribute to the treatm빅 카지노t of pati빅 카지노ts in Japan

About soft tissue sarcoma
Soft tissue sarcoma is an intractable malignancy which develops in the soft tissues (muscles^*2

About PharmaMar
PharmaMar is the world-leading biopharmaceutical company in advancing cancer care through the discovery and developm빅 카지노t of innovative marine-derived anticancer drugs

1. As of October, 2015
2. 000 “malignance of mesothelioma and soft tissue” pati빅 카지노ts

Product Summary

브랜드 이름	25 mg and 1 mg IV Infusion
Nonproprietary name	trabectedin
Indication	Soft tissue sarcoma
Dosage and administration	trabectedin is normally administered via intrav빅 카지노ous infusion in a dose of 1
Date of manufacturing and marketing approval	빅 카지노ptember 28, 2015
Date listed on the NHI reimbursem빅 카지노t price list	November 26, 2015
Date of product launch in Japan	December 7, 2015
Packaging	Yondelis IV Infusion 0 Yondelis IV Infusion 1 mg: 1 vial
NHI reimbursem빅 카지노t price	Yondelis IV Infusion 0 Yondelis IV Infusion 1 mg: 197
Manufacturing Distributor	Taiho Pharmaceutical Co